NAGOYA, Japan—October 2nd, 2026—PharmaBio Corporation (Representative Director and CEO: Hitoshi Kusano) today announced that the Phase I/IIa clinical trial (PAMyCA Trial) of the regenerative medical product PAL-222 for myopic chorioretinal atrophy achieved its primary endpoint, demonstrating the suppression of the expansion of the chorioretinal atrophy area. The top-line results also indicated the potential for maintaining visual function and a favorable safety profile.
NEWS
PharmaBio Achieves Primary Endpoint in Phase I/IIa Clinical Trial (PAMyCA Trial) of PAL-222, a Human (Allogeneic) Adipose-Derived Mesenchymal Stromal Cell Sheet, for Myopic Chorioretinal Atrophy
CONTACT US
For more details, questions, and quotes about PharmaBio’s services,
please use the email form.